Latest Breaking News On - Janssen scientific affairs - Page 5 : comparemela.com

Janssen Announces Positive Topline Results for JNJ-2113 - a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

Janssen Announces Positive Topline Results for JNJ-2113 - a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesLloyd millerThompson jrRobert bissonnetteJanssen scientific affairsCollaboration agreement with protagonist therapeutics incJanssen pharmaceutical companiesNational psoriasis foundationEveryday healthJanssen biotech for the continued developmentJanssen pharmaceutical companies of johnsonJanssen biotech incDecision resources internal claims researchExchange commissionCompanies of johnson

Janssen Announces Positive Topline Results for JNJ-2113--a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from its Phase 2b FRONTIER 1 clinical trial.

Spring houseBritish columbiaUnited statesUnited kingdomRobert bissonnetteLloyd millerBridget kimmelJanssen research developmentExchange commissionJanssen biotech incNational psoriasis foundationPatient preferenceJanssen biotech for the continued developmentJanssen pharmaceutical companiesEveryday healthTruven health analytics data

AdaptiveCME: Exploring the Role of Genetic Testing in the Diagnosis and Management of Late Onset Alzheimer s Disease

AdaptiveCME: Exploring the Role of Genetic Testing in the Diagnosis and Management of Late Onset Alzheimer s Disease
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Georgetown universityDistrict of columbiaUnited statesNew yorkColumbia universityAlexa lasekChristiane reitzR scott turnerSusan dennerCognition healthAmerican academyBiogen idecMemory disorders programLilly united statesAmerican nurses credentialing centerDepartment of neurology

ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL

Second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplant in patients with early relapsed or refractory large B-cell lymphoma.

United statesGenentech rocheMorphosys incyteJason westinLymphoma clinical research programJanssen scientific affairsBristol myers squibbDepartment of lymphomaUniversity of texas md anderson cancer centerNew england journalAggressive lymphomaCancer centerBristol myersIksuda therapeuticsMonte rosa therapeuticsAxi cel

TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial

TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Spring houseUnited statesScandj rheumatolLaura coatesTerence rooneyZismand comorbiditiesJanssen pharmaceutical companies of johnsonJanssen pharmaceutical companiesDevices agencyUniversity of oxfordStanford health assessment questionnaireArthritis foundationJanssen scientific affairsEuropean congressNone of the janssen pharmaceutical companiesJanssen research development